WST West Pharmaceutical Services
Recovery is real and the moat is intact, but $27.6B prices in a decade of growth injectables can't deliver.
The story
West makes elastomer stoppers, plungers and containment components for injectable drugs. Its moat is that customers write its components into their regulatory filings, so switching means requalifying with regulators. After the post-COVID destocking, revenue has picked back up (TTM $3.40B vs $3.07B in the last fiscal year). Demand from GLP-1 and biologics for higher-value components, plus EU Annex 1 rules on sterile manufacturing, is improving the product mix. It is a mature, high-quality compounder with a long but not unlimited reinvestment runway.
Facts changed modestly. TTM growth of about 11% and a 23.5% margin show recovery running ahead of my prior take, so I raised year-1 growth from 8% to 10% (a 25% relative move) and the target margin from 23.5% to 25% (mix shift to high-value components, below the 2021-22 peak). Sales-to-capital edges up to 1.15 because capex has normalized to about D&A. Beta, failure probability, terminal growth and the 10-year horizon are unchanged because the moat and life cycle are the same. Even with these upgrades, value lands well below $397. The market needs mid-teens growth sustained for a decade or margins near 30%, and neither is plausible for a component supplier this size.
Value drivers
| Revenue growth (Y1) | 10.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 25.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.15 |
| Beta | 0.88 |
| Failure probability | 0.8% |
| Cost of capital (WACC) | 9.0% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 4.55B |
| PV of terminal value | 6.84B |
| Equity value | 11.88B |
| ÷ shares → per share | $170.52 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.74B | 10.0% | 23.8% | 708.79M | 295.37M | 413.43M | 379.35M |
| 2 | 4.08B | 9.2% | 24.1% | 784.07M | 299.63M | 484.43M | 407.86M |
| 3 | 4.43B | 8.4% | 24.4% | 861.02M | 299.66M | 561.35M | 433.65M |
| 4 | 4.76B | 7.7% | 24.7% | 938.59M | 295.04M | 643.55M | 456.17M |
| 5 | 5.09B | 6.9% | 25.0% | 1.02B | 285.43M | 730.18M | 474.91M |
| 6 | 5.40B | 6.1% | 25.0% | 1.08B | 270.65M | 807.03M | 481.62M |
| 7 | 5.69B | 5.3% | 25.0% | 1.14B | 250.64M | 884.52M | 484.34M |
| 8 | 5.95B | 4.6% | 25.0% | 1.19B | 225.50M | 961.36M | 483.03M |
| 9 | 6.18B | 3.8% | 25.0% | 1.23B | 195.52M | 1.04B | 477.70M |
| 10 | 6.36B | 3.0% | 25.0% | 1.27B | 161.13M | 1.11B | 468.50M |
Key risks
- GLP-1 volume concentration and pricing pressure as pen/autoinjector formats or oral alternatives shift component demand
- Customer destocking or biologics pipeline slowdown repeating the 2023-24 air pocket
- Contract-manufacturing segment (Daikyo/CM) margin dilution and capex overruns on HVP capacity expansion
Catalysts
- Sustained double-digit HVP organic growth and margin recovery above 25% in coming quarters
- Annex 1 compliance-driven upgrades and new GLP-1 capacity coming online in 2027